Effect of Lixu Jieyu Recipe in Treating 75 Patients with Chronic Fatigue Syndrome
ZHANG Zhen-xian,WU Li-li,CHEN Min,et al Department of Integrative Medicine,Yueyang Hospital,Shanghai University of Traditional Chinese Medine,Shanghai (200437)
Objective To investigate the effective Chinese medicine treatment of chronic fatigue syndrome (CFS). Methods Seventy-five CFS patients meeting the inclusive criteria were enrolled from March 2007 to April 2008 and randomized into two groups. The 40 patients in the treated group were orally treated with Lixu Jieyu Recipe (LJR,consisted of milkvetch root 30 g,kudzuvine root 30 g,asiabell root 15 g,red sage root 10 g,aizoon stonecrop 15 g,epimeddium herb 10 g,curcuma root 10 g,and grassleaved sweetflag rhizome 10 g,made into 200 mL of decoction),for 100 mL twice a day. The 35 patients in the control group were treated with vitamin B tablets (10 mg twice a day),adenosine triphsphate (ATP,20 mg,thrice a day) and Oryzanol tablets (20 mg thrice a day). The laboratory indicators including serum immunoglobulins (IgG,IgA,IgM,IgE),blood immune cells,as T-cells (Th and Ts),B-cells,natural killer cells,as well as CD4/CD8 ratio were measured before and after 3-month treatment. Results After treatment the difference in scores of fatigue symptoms between the two groups was significant (P0.01),the scores of various SCL-90 factors and the total score significantly reduced in the treated group after treatment (P0.01). Levels of the immunoglobulins measured before treatment were in an equilibrium state,they all were unchanged after treatment in both groups (P0.05),and showed no significant difference between groups either before or after treatment. As for the immune cells,significant increase of the lowered Th,Ts cells,and decrease of CD4/CD8 ratio were found in both groups after treatment (P0.05),but the improvement was more significant in the treated group,so the difference between groups in these indices after treatment also showed statistical significance (P0.05). Conclusion LJR shows superiority in treating CFS.